Insmed (INSM) Stock Valuation After Pullback And Rare Disease Pipeline Debate

Simply Wall St.06-16

Insmed (INSM) has been drawing attention from investors after recent trading activity, as they weigh the company’s rare disease portfolio, including ARIKAYCE and late stage programs like brensocatib ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643578193?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-16 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643578193","market":"nz","top_or_hot":-1,"title":"Insmed (INSM) Stock Valuation After Pullback And Rare Disease Pipeline Debate","media":"Simply Wall St.","content":"<div>\n<p>Insmed (INSM) has been drawing attention from investors after recent trading activity, as they weigh the company’s rare disease portfolio, including ARIKAYCE and late stage programs like brensocatib ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-stock-valuation-after-pullback-and-rare-disease\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insmed (INSM) Stock Valuation After Pullback And Rare Disease Pipeline Debate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsmed (INSM) Stock Valuation After Pullback And Rare Disease Pipeline Debate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 06:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-stock-valuation-after-pullback-and-rare-disease><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Insmed (INSM) has been drawing attention from investors after recent trading activity, as they weigh the company’s rare disease portfolio, including ARIKAYCE and late stage programs like brensocatib ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-stock-valuation-after-pullback-and-rare-disease\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-stock-valuation-after-pullback-and-rare-disease","article_id":"2643578193","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-insm/insmed/news/insmed-insm-stock-valuation-after-pullback-and-rare-disease","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643578193","pubTimestamp":1781562369,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Insmed (INSM) has been drawing attention from investors after recent trading activity, as they weigh the company’s rare disease portfolio, including ARIKAYCE and late stage programs like brensocatib and treprostinil palmitil inhalation powder.\nSee our latest analysis for Insmed.\nInsmed’s share price has retreated from recent highs, with the latest close at US$97.46 and the 90 day share price return down 32.29%, even though the 3 year total shareholder return is very large at about 4x. Recent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"回调和罕见病管道争论后的Insmed(INSM)股票估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1.5},"content_text":"Insmed (INSM) has been drawing attention from investors after recent trading activity, as they weigh the company’s rare disease portfolio, including ARIKAYCE and late stage programs like brensocatib and treprostinil palmitil inhalation powder. See our latest analysis for Insmed. Insmed’s share price has retreated from recent highs, with the latest close at US$97.46 and the 90 day share price return down 32.29%, even though the 3 year total shareholder return is very large at about 4x. Recent trading swings appear to reflect shifting views on the risk and potential of its rare disease pipeline rather than any single headline event. If you are following Insmed because of its late stage pipeline, it can also be useful to size up other healthcare AI opportunities using our screener for 39 healthcare AI stocks With Insmed’s share price pulling back and the stock trading at what some might view as a steep discount to certain intrinsic estimates, the key question is whether this is a genuine opportunity or if the market already reflects the company’s future growth. AdvertisementMost Popular Narrative: 51.3% Undervalued At a last close of US$97.46, the most followed narrative pegs Insmed’s fair value at US$200.00, creating a wide gap that investors are actively debating.  The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.  Read the complete narrative. Want to see how this story is built? Analysts are stacking aggressive revenue expansion, margin shift and a rich future earnings multiple into one valuation blueprint. Result: Fair Value of $200.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on timely approvals and payer support. Any FDA delays or tougher reimbursement terms could quickly challenge the upbeat growth narrative investors are debating. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Another View: Multiples Paint a Tougher Picture The popular undervalued story leans heavily on future cash flows, but the current P/S of 25.8x tells a tougher story. It sits well above the US Biotechs average of 10.3x and above a fair ratio of 18.8x, which points to meaningful valuation risk if growth stumbles or is pushed out. Before leaning too hard on long term forecasts, it can help to test whether that P/S gap matches your own expectations for Insmed’s pipeline and commercial execution, or whether it leaves too little room for error. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:INSM P/S Ratio as at Jun 2026Next Steps If this mix of optimism and concern feels familiar, act while the debate is still live by reviewing the 3 key rewards and 1 important warning sign Looking for more investment ideas? If Insmed is on your watchlist, do not stop there. Widen your search now or you risk missing other stocks that might better fit your goals.  Spot potential bargains early by scanning the 47 high quality undervalued stocks that combine quality fundamentals with pricing that some investors may find appealing. Build a sturdier core for your portfolio by checking the solid balance sheet and fundamentals stocks screener (48 results) that focus on financial strength and resilience. Get ahead of the crowd by reviewing the screener containing 20 high quality undiscovered gems that highlight lesser known companies with solid underlying metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643578193","isCrawlerRequest":true}